Glipizide (Glucotrol)

Subscribe to Selected New Research on Glipizide

191 relevant articles (24 outcomes, 39 trials/studies) found for this Drug

Description: An oral hypoglycemic agent which is rapidly absorbed and completely metabolized.

Also Known As:

Glucotrol; Alphapharm Brand of Glipizide; Glibenese Brand of Glipizide; Glupitel; K-4024; Kenfarma Brand of Glipizide; Lacer Brand of Glipizide; Lilly Brand of Glipizide; Melizide; Mindiab; Minidiab; Minodiab; Ozidia; Pfizer Brand of Glipizide; Pharmacia Brand of Glipizide; K 4024; K4024; Glidiazinamide; Glydiazinamide; Glypidizine; Pyrazinecarboxamide, N-(2-(4-((((cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-5-methyl-

Relationship Network

Drug Context: Research Results

Organic Chemicals: 40

Sulfur Compounds: 81

Sulfones: 120

Sulfonylurea Compounds: 28

Glipizide: 191

metaglip

Experts

1.	Williams, William: 2 articles (06/2007 - 10/2003)
2.	Bone, Hans-Georg: 1 article (06/2007)
3.	Traber, Daniel L: 1 article (06/2007)
4.	Bröking, Katrin: 1 article (06/2007)
5.	Ertmer, Christian: 1 article (06/2007)
6.	Morelli, Andrea: 1 article (06/2007)
7.	Stubbe, Henning: 1 article (06/2007)
8.	Daudel, Fritz: 1 article (06/2007)
9.	Westphal, Martin: 1 article (06/2007)
10.	Hucklenbruch, Christoph: 1 article (06/2007)

Related Diseases

1.	Type 2 Diabetes Mellitus (MODY) 09/01/2000 - "Quality of life was improved compared with baseline after 12 weeks' treatment with glipizide GITS 5 to 20 mg/day plus diet in a US double-blind, placebo-controlled trial in 569 patients with type 2 diabetes mellitus" 12/01/1994 - "Comparative efficacy of a once-daily controlled-release formulation of glipizide and immediate-release glipizide in patients with NIDDM." 09/01/2006 - "OBJECTIVE: The aim of this study was to compare the efficacy and tolerability of a sustained-release glipizide (GSR) formulation with those of immediate-release glipizide (GIR) in Chinese patients with type 2 diabetes mellitus" 09/01/2006 - "Sustained-release versus immediate-release glipizide for treatment of type 2 diabetes mellitus in chinese patients: A randomized, double-blind, double-dummy, parallel-group, 12-week clinical study." 08/01/1990 - "In the second study, the diurnal glycemic excursions in 8 NIDDM patients chronically and continuously (24 h/day) exposed to glipizide (2.5-7.5 mg 3 times/day) were similar when the drug was taken 30 min before each of the three main meals and when taken immediately before the meals" Get all the results and reference details, order at left...
2.	Hyperglycemia 04/01/1995 - "During the course of the treatment and follow-up, hyperglycemia occurred in 6 of 10 subjects in the no treatment group, 6 of 10 in the placebo group, and 2 of 10 in the glipizide treatment group" 03/01/1976 - "In ten out of twenty patients "excellent" to "good" control of hyperglycemia was achieved with glipizide and two patients evidenced "fair" control" 10/01/2005 - "However, despite a salient effect of glipizide on the hyperglycemia of the mice, there was no effect on the time to occlusive thrombus formation (13.2 +/- 0.9 min, n = 4) compared with placebo-treated mice" 07/01/1995 - "The effect of hyperglycemia on glipizide absorption in NIDDM patients." 01/01/1994 - "A standard dose of the oral sulfonylurea glipizide (200 micrograms/100 g), administered 15 min before a 1-h restraint stress to intact or 80% pancreatectomized rats, produced total suppression of the stress-induced hyperglycemia-hypoinsulinemia, an effect followed by a significant post-stress hypoglycemia of 1 h duration" Get all the results and reference details, order at left...
3.	Hypoglycemia (Reactive Hypoglycemia) 06/01/1998 - "This is the first report to describe the delayed onset of hypoglycemia in a child after ingestion of one tablet of glipizide" 10/01/1980 - "The study of the kinetics of hypoglycemia induced by glipizide (second generation hypoglycemic sulfonamide) was carried out on the normal conscious dog" 05/01/2004 - "This profile of glipizide GITS AM is therapeutically attractive, as it is consistent with the potential for a reduced risk of hypoglycemia." 08/01/2003 - "Glipizide did not affect total pancreatic blood flow, but decreased islet blood flow by 50% in the presence of hypoglycemia" 01/01/1999 - "Delayed hypoglycemia after ingestion of a single glipizide tablet." Get all the results and reference details, order at left...
4.	Weight Loss (Weight Reduction) 04/01/1985 - "Hypocaloric liquid formula diets were given for one month to 20 moderately obese patients with non-insulin-dependent diabetes mellitus divided into two equal groups; group 1 was treated with weight loss alone; group 2 received glipizide in addition to the hypocaloric diet" 03/01/2007 - "Sitagliptin was generally well tolerated, with a lower risk of hypoglycaemia relative to glipizide and with weight loss compared with weight gain with glipizide." 03/01/2007 - "Sitagliptin led to weight loss (change from baseline =-1.5 kg) compared with weight gain (+1.1 kg) with glipizide [between-treatment difference (95% confidence interval) =-2.5 kg (-3.1, -2.0); p < 0.001]" 07/01/1994 - "In conclusion, metformin gave better glycaemic control than glipizide, with weight loss rather than weight gain in obese Type 2 patients." 01/01/1992 - "Of 23 patients with non-insulin-dependent diabetes mellitus (NIDDM), whose fasting blood glucose had not reached less than or equal to 6.0 mmol.l-1 after 10 weeks of dietary regulation, 15, who had had a weight reduction of -2.8 kg by dietary control, did achieve a fasting blood glucose less than or equal to 6.0 mmol.l-1 after addition of less than or equal to 20 mg glipizide daily" Get all the results and reference details, order at left...
5.	Diabetes Mellitus 11/30/1983 - "Our observations show that glipizide therapy is effective in certain patients with noninsulin-dependent diabetes mellitus over a prolonged time period" 09/13/2006 - "Glipizide matrix transdermal systems for diabetes mellitus: preparation, in vitro and preclinical studies." 09/01/1996 - "STUDY OBJECTIVES: To determine the pharmacokinetics and pharmacodynamics of glipizide after a single dose and 12 weeks of dosing in patients with type II diabetes mellitus, and evaluate the influence of aging" 03/01/2006 - "Glipizide is a second-generation sulfonylurea commonly used to treat patients with noninsulin-dependent diabetes mellitus" 06/01/2002 - "Pharmacokinetics and pharmacodynamics of extended-release glipizide GITS compared with immediate-release glipizide in patients with type II diabetes mellitus." Get all the results and reference details, order at left...
62 Diseases and 191 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Insulin (Novolin)
2.	Glucose (Dextrose)
3.	Glyburide (Glibenclamide)
4.	C-Peptide
5.	Lipoproteins (Lipoprotein)
6.	Metformin (Glucophage)
7.	Chlorpropamide
8.	Blood Glucose (Blood Sugar)
9.	glimepiride (Amarel)
10.	repaglinide (Prandin)
86 Drugs and Important Bio-Agents and 133 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Aftercare (After-Treatment)
2.	Diet Therapy (Therapy, Diet)
3.	Transplants (Transplant)
4.	Ligation
5.	Home Nursing (Nursing, Home)
5 Therapies and Procedures and 8 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>